EP2320917A4 - Procédés de prévention, d'arrêt ou d'inversion de la tumorigenèse et d'identification de composés capables de ceux-ci - Google Patents

Procédés de prévention, d'arrêt ou d'inversion de la tumorigenèse et d'identification de composés capables de ceux-ci

Info

Publication number
EP2320917A4
EP2320917A4 EP09803219A EP09803219A EP2320917A4 EP 2320917 A4 EP2320917 A4 EP 2320917A4 EP 09803219 A EP09803219 A EP 09803219A EP 09803219 A EP09803219 A EP 09803219A EP 2320917 A4 EP2320917 A4 EP 2320917A4
Authority
EP
European Patent Office
Prior art keywords
arresting
preventing
methods
same
compounds capable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09803219A
Other languages
German (de)
English (en)
Other versions
EP2320917A1 (fr
Inventor
Yoshiaki Ito
Kosei Ito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of EP2320917A1 publication Critical patent/EP2320917A1/fr
Publication of EP2320917A4 publication Critical patent/EP2320917A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP09803219A 2008-07-29 2009-07-29 Procédés de prévention, d'arrêt ou d'inversion de la tumorigenèse et d'identification de composés capables de ceux-ci Withdrawn EP2320917A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8448608P 2008-07-29 2008-07-29
PCT/SG2009/000268 WO2010014043A1 (fr) 2008-07-29 2009-07-29 Procédés de prévention, d'arrêt ou d'inversion de la tumorigenèse et d'identification de composés capables de ceux-ci

Publications (2)

Publication Number Publication Date
EP2320917A1 EP2320917A1 (fr) 2011-05-18
EP2320917A4 true EP2320917A4 (fr) 2011-11-09

Family

ID=41610589

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09803219A Withdrawn EP2320917A4 (fr) 2008-07-29 2009-07-29 Procédés de prévention, d'arrêt ou d'inversion de la tumorigenèse et d'identification de composés capables de ceux-ci

Country Status (2)

Country Link
EP (1) EP2320917A4 (fr)
WO (1) WO2010014043A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016017132B1 (pt) * 2014-01-28 2024-01-30 Quest Diagnostics Investments Incorporated Métodos para identificar uma zona de célula tipo tronco de câncer, uma zona de transição de adenoma-adenocarcinoma, um tumor de cólon, células-tronco de câncer, um indivíduo com câncer colorretal provável de responder favoravelmente ao tratamento com uma terapia alvejada pela via nf-kb, um indivíduo com perda genômica de 18q/smad4 e de 10q/pten, para diagnosticar um indivíduo com alto grau de adenoma de cólon e adenocarcinoma inicial, e para determinar a probabilidade de um tumor de cólon em um indivíduo passar por uma transformação invasiva se deixado sem tratamento e a probabilidade de um indivíduo com câncer colorretal (crc) responder favoravelmente ao tratamento com uma terapia alvejada pela via tgf-beta, e, kit para identificar uma região de transição de (...).

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002061069A1 (fr) * 2001-01-29 2002-08-08 Suk-Chul Bae Gene runx3 montrant une activite antitumorale et utilisation
WO2006057623A1 (fr) * 2004-11-29 2006-06-01 National University Of Singapore Anticorps runx3 et procede de collecte

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070237770A1 (en) * 2001-11-30 2007-10-11 Albert Lai Novel compositions and methods in cancer
US7611847B2 (en) * 2005-06-01 2009-11-03 Agency For Science, Technology And Research Method for identifying an intestinal phenotype
US7507536B2 (en) * 2005-10-07 2009-03-24 The Johns Hopkins University Methylation markers for diagnosis and treatment of ovarian cancer
WO2008070082A2 (fr) * 2006-12-04 2008-06-12 The Johns Hopkins University Acides microribonucléiques spécifiques de cellule souche de progéniteur et leurs utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002061069A1 (fr) * 2001-01-29 2002-08-08 Suk-Chul Bae Gene runx3 montrant une activite antitumorale et utilisation
WO2006057623A1 (fr) * 2004-11-29 2006-06-01 National University Of Singapore Anticorps runx3 et procede de collecte

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KATOH MASARU: "Dysregulation of stem cell signaling network due to germline mutation, SNP, Helicobacter pylori infection, epigenetic change and genetic alteration in gastric cancer.", CANCER BIOLOGY & THERAPY JUN 2007 LNKD- PUBMED:17568183, vol. 6, no. 6, June 2007 (2007-06-01), pages 832 - 839, XP002658187, ISSN: 1555-8576 *
See also references of WO2010014043A1 *
WETERING VAN DE M ET AL: "The ss-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells", CELL, CELL PRESS, US, vol. 111, 18 October 2002 (2002-10-18), pages 241 - 250, XP002324236, ISSN: 0092-8674, DOI: 10.1016/S0092-8674(02)01014-0 *

Also Published As

Publication number Publication date
WO2010014043A1 (fr) 2010-02-04
EP2320917A1 (fr) 2011-05-18

Similar Documents

Publication Publication Date Title
NO2022013I1 (en) Finerenone and its salts, solvates and solvates of the salts thereof
IL269858A (en) Pyridone and aza-pyridone compounds, pharmaceutical composition and kits comprising the same and uses thereof
IL254218A0 (en) Pipedrine-bridged compounds of the quinoxaline-converted type and their use
EP2374912A4 (fr) Revêtement antibactérien, ses procédés de préparation et pièce métallique contenant le revêtement
EP2153838A4 (fr) Agent anti-norovirus et composition le comprenant
EP2247165A4 (fr) Dispositif d'éclairage et dispositif d'affichage le comprenant
IL206127A0 (en) Azolylmethyloxiranes, use thereof and agents containing the same
EP2253227A4 (fr) Agent de renforcement de salinité et aliment ou boisson le contenant
IL211131A0 (en) Inhbb epitope and vaccines containing the same
EP2354161A4 (fr) Anticorps anti-nr10, et utilisation correspondante
HK1168843A1 (zh) 取代的喹喔啉型呱啶化合物及其用途
HK1131140A1 (en) Substituted prolinamides, and the use thereof
EP2287155A4 (fr) Composé d acylthiourée ou son sel, et utilisation du composé ou du sel
IL221906B (en) pde10 suppressor compounds, preparations containing them and their uses
IL213043A0 (en) Lantibiotic carboxyamide derivatives, compositions comprising the same and uses thereof
EP2307052A4 (fr) Agents anti-bêta-2-microglobuline et leur utilisation
EP2351732A4 (fr) Nouveau composé de ramaline et utilisation de celui-ci
EP2457092A4 (fr) Biomarqueur du cancer et son utilisation
IL207639A0 (en) Pyrrolopyrimidinecarboxamide compounds, compositions comprising the same and uses thereof
SI2354161T1 (sl) Anti-NR10 protitelo in njegova uporaba
GB0719592D0 (en) Compound, use and method
IL208168A0 (en) Tetrahydroisoquinoline derivatives, compositions comprising the same and use thereof
HRP20160578T1 (hr) Supstituirani furankarboksamidi i njihova upotreba
EP2192122A4 (fr) Composés dithiolopyrrolones, leur préparation et leur utilisation
EP2320917A4 (fr) Procédés de prévention, d'arrêt ou d'inversion de la tumorigenèse et d'identification de composés capables de ceux-ci

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110211

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/574 20060101ALI20110908BHEP

Ipc: C12Q 1/00 20060101ALI20110908BHEP

Ipc: A61K 35/00 20060101AFI20110908BHEP

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20111012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120201